Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunosuppressive therapy with Certican (everolimus) after lung transplantation.

Trial Profile

Immunosuppressive therapy with Certican (everolimus) after lung transplantation.

Phase of Trial: Phase III

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Lung transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Apr 2016 Results published in the American Journal of Transplantation
    • 07 Dec 2011 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 07 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top